Development of a vaccine for the prevention of AIDS, a critical appraisal

Vaccine

Volumn 10, Issue 14, 1992, Pages 1039-1052

  Karzon, David T ^a   Bolognesi, Dani P ^b   Koff, Wayne C ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

AIDS; animal models; clinical trials; ethical legal issues; HIV; pathogenesis; vaccine development

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOTOXIC T LYMPHOCYTE; ETHICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; LEGAL ASPECT; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMAL; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; EPITOPES; ETHICS, MEDICAL; GENES, STRUCTURAL, VIRAL; HEALTH POLICY; HIV ANTIBODIES; HIV ANTIGENS; HIV-1; HUMAN; INTERNATIONAL COOPERATION; MOLECULAR SEQUENCE DATA; PRIMATES; SAFETY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIV; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0026539681     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(92)90114-Y     Document Type: Article

References (108)

1. Pathogenesis and pathology of viral infections
2. The immunological principles of vaccination
3. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants
4. Acute AIDS retrovirus infection; definition of a clinical illness associated with seroconversion
5. Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection
6. High titres of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection
7. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection
8. Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease
9. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
10. Prevention of HIV infection by passive immunization with HIV immunoglobulin
11. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients
12. Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene
13. Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160
14. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
15. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
16. Binding of HTLV-III/LAV to T4 + T cells by a complex of the 110K viral protein and the T4 molecule
17. Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein
18. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1
19. pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane
20. Antigenic variation in HIV
21. The role of the V3 loop of gp120 in HIV infection
22. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1
23. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1
24. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody
25. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody
26. Evidence for the direct involvement of the rhinovirus canyon in receptor binding
27. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120
28. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans
29. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains
30. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120
31. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees
32. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells
33. HIV susceptibility conferred to human fibroblasts by cytomegalovirus-induced Fc receptor
34. Peptide component vaccine engineering: Targeting the AIDS virus
35. HIV epitopes recognized by cytotoxic T-lymphocytes
36. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition
37. A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160
38. Minireview: Anti-HIV-1 ADCC
39. The mucosal immune system: from fundamental concepts to vaccine development
40. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals
41. SIV vaccines, 1991 a year in review
42. Protection of macaques against SIV infection by subunit vaccine of SIV envelope glycoprotein gp160
43. The role of HIV-specific T cells in the pathogenesis and prevention of AIDS
44. Helper independent recombinant adenovirus vectors expression of HIV env or HBV surface antigen
45. Live salmonella as vaccines and carriers of foreign antigenic determinants
46. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines
47. HIV-1 neutralization directed to epitopes other than linear V3 determinants
48. Identification of homologous regions in human immunodeficiency virus gp41 and human MHC class II beta I domain
49. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus
50. New AIDS vaccine candidates: antigen delivery and design
51. Long-term high-titre neutralizing activity induced by octameric synthetic HIV-1 antigen
52. Current status of immunological adjuvants
53. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine
54. The expression of hybrid HIV:Ty virus-like particles in yeast
55. Liposomes as immunological adjuvants: antigen incorporation studies
56. Induction of cytotoxic T cells by immunization with complexes of purified HIV-1 envelope protein
57. Universal vaccine carrier: liposomes that provide T dependent help to weak antigens
58. Hepatitis B synthetic immunogen comprised of nucleocapsid T cell sites and an envelope B cell epitope
59. Biodegradable microspheres as a vaccine delivery system
60. Expression of Il-1 by vaccinia virus: enhanced immune responses to vaccinia and co-expressed antigens
61. Heterogeneity of cytokine secretion patterns by helper T cells
62. Cholera toxin as a mucosal adjuvant
63. Planning for HIV vaccine trials: the World Health Organization perspective
64. The use of primates in experimental viral infections—rubella and the rubella syndrome
65. Live attenuated poliovaccines
66. Mumps vaccine
67. The preparation and use of yellow fever vaccine
68. Feline immunodeficiency virus as a model for AIDS vaccination
69. Progress with HIV vaccines
70. The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function
71. Transfer of a functional human immune system to mice with severe combined immunodeficiency
72. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
73. Anti-cell antibody in macaques
74. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans
75. Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory
76. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine
77. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons
78. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
79. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein
80. 1
81. Human immunodeficiency virus type-1 neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping
82. HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1
83. A novel method for the purification of HIV-1 p24 protein from hybrid Ty virus-like particles (Ty-VLPs)
84. Vaccination of vaccinia-naive adults with HIV-1 gp160 recombinant vaccinia (HIVAC-1e) in a blinded controlled, randomized clinical trial
85. Immunization against AIDS in humans
86. A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS
87. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection
88. Antibody enhanced infection by HIV-1 via Fc receptor mediated entry
89. Human trials of AIDS vaccines: current status and future directions
90. Interaction between the human T cell lymphotropic virus type IIIb envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion
91. HIV-1 gp120 as a subunit vaccine
92. Sequence variability in human immunodeficiency viruses: pattern and process in viral evolution
93. The emergence of simian/human immunodeficiency viruses
94. Development and testing of AIDS vaccines
95. Transmission of the human immunodeficiency virus
96. Advances in AIDS vaccine development: a global applied research strategy could expedite the development and testing of vaccine candidates
97. Prospects for Vaccines against HIV Infection
98. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection